Status:

COMPLETED

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Lead Sponsor:

Centre Antoine Lacassagne

Conditions:

Lymphoma

Eligibility:

All Genders

65-80 years

Phase:

PHASE2

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as doxorubicin, vincristine, and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping the...

Detailed Description

OBJECTIVES: Primary * Determine event-free survival of patients with large B-cell lymphoma treated with CHOP-R followed by consolidation therapy. Secondary * Determine overall survival. * Evaluate...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed large B-cell lymphoma
  • Stage I, II, III, or IV disease
  • Bone marrow or lymph node involvement by small cell lymphoma allowed
  • No serious, progressive pathology (at investigator's discretion)
  • CD20-positive disease
  • Measurable disease
  • No prior indolent lymphoma, treated or not
  • No meningeal or CNS lymphoma
  • PATIENT CHARACTERISTICS:
  • International prognostic index \< 2 (adjusted for age)
  • Life expectancy \> 3 months
  • ALT and AST ≤ 2.5 times upper limit of normal
  • Bilirubin ≤ 30 mmol/L
  • Creatinine ≤ 150 μmol/L
  • HIV, hepatitis B virus, and hepatitis C virus negative (unless after vaccine)
  • No contraindication to chemotherapy or immunotherapy
  • No cancer in the past 5 years except basal cell skin cancer or carcinoma in situ of the cervix
  • No contraindication to a venous catheter
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • At least 30 days since prior and no other concurrent investigational treatment
  • No prior therapy
  • No concurrent participation in another clinical study

Exclusion

    Key Trial Info

    Start Date :

    May 1 2007

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    October 1 2010

    Estimated Enrollment :

    30 Patients enrolled

    Trial Details

    Trial ID

    NCT00690560

    Start Date

    May 1 2007

    End Date

    October 1 2010

    Last Update

    September 30 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Centre Antoine Lacassagne

    Nice, France, 06189